中国接受长期抗逆转录病毒治疗的HIV感染儿童和青少年耐药特征及影响因素:多中心观察性研究
该多中心观察性队列研究纳入562例15岁前启动抗逆转录病毒治疗(ART)的HIV感染儿童和青少年,对93例病毒学失败者行基因型耐药检测,68例(73.1%)携带至少1个主要耐药突变,起始ART年龄、B亚型及初始含NNRTI方案与耐药突变独立相关。
要点
- 93例长期ART后病毒学失败者中68例(73.1%)检出至少1个主要耐药突变。
- NRTI、NNRTI及双类耐药分别占48.4%、63.4%和38.7%,PI耐药仅占3.2%。
- 40例耐药者中55.0%在次优方案下持续病毒学失败,失败时长与主要突变数正相关(r=0.504,P=0.001)。
核心结论
- 长期治疗的HIV感染儿童和青少年中耐药突变发生常见,耐药者中持续病毒学失败普遍,亟需及时基因型检测和新的儿童友好剂型。
研究设计与样本
- 在中国五个中心开展观察性队列研究,筛查所有启动ART时年龄小于15岁的参与者。
- 将病毒载量(VL)≥400拷贝/mL的病毒学失败者纳入基因型耐药检测。
- 进行Logistic回归分析,并在自HIV诊断以来有完整VL结果的耐药亚组中分析主要突变的累积。
主要发现
- 562例合格参与者中,93例治疗失败者(ART中位10.0年)成功扩增蛋白酶和逆转录酶区。
- 68例(73.1%)携带至少1个主要突变;NRTI、NNRTI和双类耐药分别占48.4%、63.4%和38.7%,仅3.2%对PI耐药。
- 起始ART年龄(aOR=0.813,95%CI 0.690-0.957)、B亚型(aOR=4.378,95%CI 1.414-13.560)和初始含NNRTI方案(aOR=3.331,95%CI 1.180-9.402)与耐药突变独立相关。
- 40例有额外VL数据的耐药者中,55.0%在次优方案下持续病毒学失败,估计病毒学失败时长与主要突变总数正相关(r=0.504,P=0.001)。
临床怎么用
- 作者认为,亟需及时进行基因型检测和研发新的儿童友好剂型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse the characteristics and determinants of drug resistance mutations (DRMs) in HIV-infected children and adolescents on long-term ART in China. METHODS: An observational cohort study was conducted in five centres. All participants younger than 15 years at ART initiation were screened, and those identified as having virological failure (VF) with viral load (VL) ≥ 400 copies/mL were included for genotypic resistance testing. Logistic regression analysis was performed and the accumulation of major mutations was analysed in a subgroup of resistant individuals with complete VL results since HIV diagnosis. RESULTS: Among 562 eligible participants, protease and RT regions were successfully amplified for 93 who failed treatment with a median of 10.0 years ART. Sixty-eight (73.1%) harboured ≥1 major mutations. NRTI, NNRTI and dual-class resistance accounted for 48.4%, 63.4% and 38.7%, respectively. Only 3.2% were resistant to PIs. Age at ART initiation [adjusted OR (aOR) = 0.813, 95% CI 0.690-0.957], subtype B (aOR = 4.378, 95% CI 1.414-13.560) and an initial NNRTI-based regimen (aOR = 3.331, 95% CI 1.180-9.402) were independently associated with DRMs. Among 40 resistant participants with additional VL data, 55.0% had continued VF on a suboptimal regimen and the estimated duration of VF was positively correlated with the total number of major mutations (r = 0.504, P = 0.001). CONCLUSIONS: The development of DRMs was common in children and adolescents receiving long-term treatment, and continued VF was prevalent in those with resistance. Timely genotypic testing and new child-friendly formulations are therefore urgently required.
引用
- Yan L, Yu F, Liang J, et al. Drug resistance profiles and influencing factors among HIV-infected children and adolescents receiving long-term ART: a multicentre observational study in China. J Antimicrob Chemother. 2022. PMID: 35195695. doi:10.1093/jac/dkab430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。